Drug Profile
AMXT 1501
Alternative Names: AMX-1501; AMX-513; AMX513 dicaprate; AMXT 1501 dicaprate; AMXT1501Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Aminex Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunostimulants; Polyamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase 0 Glioma
Most Recent Events
- 11 Oct 2023 Preclinical data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 21 Apr 2023 Aminex completes phase-I trial in Solid tumours(Combination therapy, In children, In adults, In adolescents, In the elderly, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03536728)
- 01 Mar 2023 Phase-0 for Glioma (Combination therapy, Late-stage disease) in USA (Intratumoural) (NCT05717153)